MX365574B - 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. - Google Patents
2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas.Info
- Publication number
- MX365574B MX365574B MX2015012736A MX2015012736A MX365574B MX 365574 B MX365574 B MX 365574B MX 2015012736 A MX2015012736 A MX 2015012736A MX 2015012736 A MX2015012736 A MX 2015012736A MX 365574 B MX365574 B MX 365574B
- Authority
- MX
- Mexico
- Prior art keywords
- cancer
- aminopyrimidin
- ones
- proliferative activities
- analogs exhibiting
- Prior art date
Links
- XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical class NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 title 1
- 230000001093 anti-cancer Effects 0.000 title 1
- 230000001028 anti-proliverative effect Effects 0.000 title 1
- 230000001747 exhibiting effect Effects 0.000 title 1
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 2
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000029725 Metabolic bone disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
Abstract
Se describen compuestos de Fórmula I (ver Fórmula) que son útiles para el tratamiento del cáncer, enfermedades autoinmunitarias y trastornos óseos metabólicos a través de la inhibición de cinas c-FMS (CSF-1R), c-KIT y/o PDGFR; estos compuestos también son útiles para el tratamiento de otras enfermedades de los mamíferos mediadas por cinasas c-FMS, c-KIT o PDGFR.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361792812P | 2013-03-15 | 2013-03-15 | |
| PCT/US2014/029661 WO2014145025A2 (en) | 2013-03-15 | 2014-03-14 | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2015012736A MX2015012736A (es) | 2016-05-31 |
| MX365574B true MX365574B (es) | 2019-06-06 |
Family
ID=51529950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015012736A MX365574B (es) | 2013-03-15 | 2014-03-14 | 2-aminopirimidin-6-onas y analogos que exhiben actividades anticancerosas y antiproliferativas. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US9181223B2 (es) |
| EP (1) | EP2968286B1 (es) |
| JP (6) | JP6165314B2 (es) |
| KR (4) | KR102628583B1 (es) |
| CN (2) | CN105120864B (es) |
| AU (5) | AU2014233411B2 (es) |
| BR (1) | BR112015022288B1 (es) |
| CA (1) | CA2903285C (es) |
| DK (1) | DK2968286T3 (es) |
| ES (1) | ES2651165T3 (es) |
| HK (1) | HK1220398A1 (es) |
| IL (4) | IL241000B (es) |
| MX (1) | MX365574B (es) |
| PH (1) | PH12015502114A1 (es) |
| PT (1) | PT2968286T (es) |
| RU (1) | RU2015143717A (es) |
| SG (1) | SG11201507660TA (es) |
| WO (1) | WO2014145025A2 (es) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461179B1 (en) | 2012-06-07 | 2013-06-11 | Deciphera Pharmaceuticals, Llc | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases |
| RU2015143717A (ru) * | 2013-03-15 | 2017-04-28 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| JP6967302B2 (ja) * | 2017-05-24 | 2021-11-17 | アビスコ セラピューティクス カンパニー リミテッド | アザアリール誘導体、その製造方法および薬学上の応用 |
| WO2018233527A1 (zh) * | 2017-06-19 | 2018-12-27 | 上海和誉生物医药科技有限公司 | 一种具有csf1r抑制活性的氮杂芳基衍生物、其制备方法和应用 |
| SG11202007198WA (en) | 2018-01-31 | 2020-08-28 | Deciphera Pharmaceuticals Llc | Combination therapy for the treatment of gastrointestinal stromal tumors |
| CA3089630A1 (en) | 2018-01-31 | 2019-08-08 | Deciphera Pharmaceuticals, Llc | Combination therapy for the treatment of mastocytosis |
| CN110845476B (zh) * | 2018-08-21 | 2022-11-18 | 上海和誉生物医药科技有限公司 | 一种高选择性csf1r抑制剂、其制备方法和在药学上的应用 |
| EP4303583A3 (en) * | 2018-12-28 | 2024-03-27 | Deciphera Pharmaceuticals, LLC | Methods of treating disorders using csf1r inhibitors cross-reference to related applications |
| EP3966207B1 (en) | 2019-05-10 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Phenylaminopyrimidine amide autophagy inhibitors and methods of use thereof |
| JP2022531932A (ja) | 2019-05-10 | 2022-07-12 | デシフェラ・ファーマシューティカルズ，エルエルシー | ヘテロアリールアミノピリミジンアミドオートファジー阻害剤およびその使用方法 |
| MX2021015628A (es) | 2019-06-17 | 2022-04-18 | Deciphera Pharmaceuticals Llc | Inhibidores de la autofagia de la amida aminopirimidina y sus metodos de uso. |
| TW202122082A (zh) | 2019-08-12 | 2021-06-16 | 美商迪賽孚爾製藥有限公司 | 治療胃腸道基質瘤方法 |
| EP4013412A1 (en) | 2019-08-12 | 2022-06-22 | Deciphera Pharmaceuticals, LLC | Ripretinib for treating gastrointestinal stromal tumors |
| EP4084778B1 (en) | 2019-12-30 | 2023-11-01 | Deciphera Pharmaceuticals, LLC | Amorphous kinase inhibitor formulations and methods of use thereof |
| EP4084779B1 (en) | 2019-12-30 | 2024-10-09 | Deciphera Pharmaceuticals, LLC | Compositions of 1-(4-bromo-5-(1-ethyl-7-(methylamino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluorophenyl)-3-phenylurea |
| BR112023009531A2 (pt) | 2020-11-18 | 2023-10-03 | Deciphera Pharmaceuticals Llc | Gcn2 e inibidores de perk quinase e métodos de uso dos mesmos |
| CN115385896A (zh) * | 2021-05-24 | 2022-11-25 | 上海和誉生物医药科技有限公司 | 一种csf-1r抑制剂中间体或其酸式盐的制备方法 |
| CN113880812A (zh) * | 2021-11-17 | 2022-01-04 | 上海皓元生物医药科技有限公司 | 一种csf-ir抑制剂的制备方法 |
| WO2023125812A1 (zh) * | 2021-12-31 | 2023-07-06 | 上海海雁医药科技有限公司 | 取代的嘧啶酮衍生物、其药物组合物及医药上的用途 |
| US11779572B1 (en) | 2022-09-02 | 2023-10-10 | Deciphera Pharmaceuticals, Llc | Methods of treating gastrointestinal stromal tumors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008046216A1 (en) * | 2006-10-18 | 2008-04-24 | Methylgene, Inc. | Kinase inhibitors and uses thereof |
| AU2007338792B2 (en) * | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| KR20110099687A (ko) * | 2008-10-29 | 2011-09-08 | 데시페라 파마슈티칼스, 엘엘씨. | 항-암과 항-증식성 활성을 나타내는 시클로프로판 아미드와 유사체 |
| US9133183B2 (en) | 2013-03-15 | 2015-09-15 | Deciphera Pharmaceuticals, Llc | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities |
| US9193719B2 (en) | 2013-03-15 | 2015-11-24 | Deciphera Pharmaceuticals, Llc | 1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities |
| RU2015143717A (ru) * | 2013-03-15 | 2017-04-28 | ДЕСИФЕРА ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | 2-Аминопиримидин-6-оны и аналоги, проявляющие противораковые и антипролиферативные действия |
-
2014
- 2014-03-14 RU RU2015143717A patent/RU2015143717A/ru not_active Application Discontinuation
- 2014-03-14 WO PCT/US2014/029661 patent/WO2014145025A2/en active Application Filing
- 2014-03-14 AU AU2014233411A patent/AU2014233411B2/en active Active
- 2014-03-14 BR BR112015022288-9A patent/BR112015022288B1/pt active IP Right Grant
- 2014-03-14 CA CA2903285A patent/CA2903285C/en active Active
- 2014-03-14 KR KR1020227016381A patent/KR102628583B1/ko active Application Filing
- 2014-03-14 CN CN201480021743.5A patent/CN105120864B/zh active Active
- 2014-03-14 SG SG11201507660TA patent/SG11201507660TA/en unknown
- 2014-03-14 EP EP14764032.0A patent/EP2968286B1/en active Active
- 2014-03-14 KR KR1020217026183A patent/KR102399891B1/ko active IP Right Grant
- 2014-03-14 US US14/214,171 patent/US9181223B2/en active Active
- 2014-03-14 KR KR1020157029134A patent/KR102293086B1/ko active IP Right Grant
- 2014-03-14 MX MX2015012736A patent/MX365574B/es active IP Right Grant
- 2014-03-14 PT PT147640320T patent/PT2968286T/pt unknown
- 2014-03-14 DK DK14764032.0T patent/DK2968286T3/en active
- 2014-03-14 KR KR1020247001621A patent/KR20240013846A/ko active Search and Examination
- 2014-03-14 CN CN201710265111.9A patent/CN107311981B/zh active Active
- 2014-03-14 JP JP2016503185A patent/JP6165314B2/ja active Active
- 2014-03-14 ES ES14764032.0T patent/ES2651165T3/es active Active
-
2015
- 2015-09-01 IL IL241000A patent/IL241000B/en active IP Right Grant
- 2015-09-14 PH PH12015502114A patent/PH12015502114A1/en unknown
-
2016
- 2016-07-19 HK HK16108583.8A patent/HK1220398A1/zh unknown
-
2017
- 2017-06-20 JP JP2017120849A patent/JP2017193567A/ja active Pending
-
2018
- 2018-07-09 IL IL260502A patent/IL260502B/en active IP Right Grant
- 2018-11-28 AU AU2018271293A patent/AU2018271293B2/en active Active
-
2019
- 2019-02-25 JP JP2019032014A patent/JP6936823B2/ja active Active
-
2020
- 2020-06-16 IL IL275422A patent/IL275422B/en unknown
- 2020-07-15 AU AU2020205294A patent/AU2020205294B2/en active Active
-
2021
- 2021-08-27 JP JP2021138625A patent/JP7169412B2/ja active Active
-
2022
- 2022-01-04 IL IL289629A patent/IL289629B2/en unknown
- 2022-06-15 AU AU2022204166A patent/AU2022204166C1/en active Active
- 2022-10-28 JP JP2022173722A patent/JP7536064B2/ja active Active
-
2024
- 2024-04-02 AU AU2024202088A patent/AU2024202088A1/en active Pending
- 2024-04-25 JP JP2024071962A patent/JP2024105360A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502114A1 (en) | 2-aminopyrimidin-6-ones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| WO2014145015A3 (en) | Imidazolidinones and analogs exhibiting anti-cancer and anti-proliferative activities | |
| PH12015502336A1 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| WO2014145029A3 (en) | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities | |
| MX2015010125A (es) | Derivados de piridazinona-amidas. | |
| MA40076A (fr) | Inhibiteurs de syk | |
| PH12015502615A1 (en) | Chemical compounds | |
| NZ758528A (en) | Bicyclic heterocycle compounds and their uses in therapy | |
| MX2017006302A (es) | Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias. | |
| MX2017008442A (es) | Uso de picolinamidas como fungicidas. | |
| EA201690316A1 (ru) | Соединения для применения в качестве иммуномодуляторов | |
| PH12016500225B1 (en) | Novel quinoline-substituted compound | |
| PH12015502737A1 (en) | Novel fused pyrimidine compound or salt thereof | |
| EA201591051A1 (ru) | Ингибиторы erk и варианты их применения | |
| EA201400178A1 (ru) | Лечение рака молочной железы | |
| EA201890572A1 (ru) | Биофармацевтические композиции | |
| NZ730334A (en) | Substituted 2-azabicycles and their use as orexin receptor modulators | |
| MX2016005760A (es) | Inhibidores de glucogeno sintasa cinasa 3 (gsk-3). | |
| MX2015008877A (es) | Conjugados de disulfuro mixto de compuestos de tienopiridina y sus usos. | |
| MX2017005578A (es) | Métodos de administración de composiciones de amantadina. | |
| MX2015013936A (es) | Compuestos de pirimidina condensada sustituida. | |
| BR112018008931A8 (pt) | ?compostos para tratamento de distúrbios hipoproliferativos? | |
| GEP20186893B (en) | Pyrazines modulators of gpr6 | |
| MX2017006899A (es) | Sintesis de polioles polimericos en polioles insaturados, polioles polimericos y su uso. | |
| IN2013DE02503A (es) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |